Loading…
← CockpitCompetitor Analysis › 6821.HK Asymchem Laboratories (Tianjin) Co., Ltd. Class HOpen in the cockpit ↗

Asymchem Laboratories (Tianjin) Co., Ltd. Class H6821.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

CDMO specializing in manufacturing active pharmaceutical ingredients and intermediates for global drugmakers.

≈ A Chinese API/CDMO manufacturer akin to a smaller LonzaMomentum strong 62
Mkt cap
$7.10B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$12.3M
20-day average traded
Fwd P/E
24.4×
forward earnings
ROIC−WACC
+2.2 pp
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$109.40
1D-4.9%
1W-11.6%
1M-21.6%
3M-13.5%
6M+16.6%
YTD+53.6%
1Y+30.2%
ATR %8.6%
52w lowhigh38.5% off high

What Asymchem Laboratories (Tianjin) does

CDMO specializing in manufacturing active pharmaceutical ingredients and intermediates for global drugmakers.

This is the Hong Kong share class of the same company as the Shenzhen listing. Drugmakers hire it first to develop a manufacturing process for a drug in trials, which can lead to long commercial supply contracts if the drug is approved, so orders build over years. COVID-treatment work temporarily boosted its sales.

In one line: A Chinese API/CDMO manufacturer akin to a smaller Lonza.

Products and services

  • Small-molecule API manufacturing
  • Process development services
  • Biologics/CGT manufacturing

Customers

  • Global biopharma and generic drug companies

Where it sits in the supply chain

  • Healthcare
  • Biopharma CDMO
  • API/pharmaceutical intermediate…

What could go right

  • Global biopharma API outsourcing growth
  • New molecule commercial manufacturing wins

What could go wrong

  • US biosecurity/outsourcing policy risk
  • Customer/program concentration risk

Moat: narrow (process know-how, customer qualification, scale). Process-chemistry expertise and regulatory-compliant manufacturing scale, hard to switch mid-program.

Headquarters: Tianjin, China · Founded: 1995 · Employees: 10,617

Named competitors

Asymchem Laboratories (Tianjin) at a glance

Size Asymchem Laboratories (Tianjin) (6821.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $7.10B, the 200th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$109.40 on 18 Nov 2026.

Performance Over six months the shares gained 16.6%, against -1.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 23.9% over the last twelve months (peer median +8.9%); the operating margin is 17.2% (peer median 13.1%).

Valuation It trades at 24.4× forward earnings against a peer median of 19.3× (6th most expensive of 15).

Capital Return on invested capital runs 2.2 points above its cost of capital (9.8% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 20266821.HK 118Peer median 99
Six months, rebased to 100: Asymchem Laboratories (Tianjin) against the median of its 20 peers (local-currency closes).

Asymchem Laboratories (Tianjin) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$8.43BHK$7.20BHK$6.21BHK$8.60BHK$11.9B
Revenue growth—+16%-28%-28%—
Gross profitHK$3.93BHK$2.87BHK$2.44BHK$4.23BHK$5.49B
EBITDAn/aHK$1.75BHK$1.23BHK$2.99BHK$4.04B
Net incomeHK$1.34BHK$1.23BHK$1.03BHK$2.51BHK$3.84B
Free cash flow-HK$809MHK$358MHK$303MHK$2.77BHK$1.37B
Capital expenditureHK$2.12BHK$1.38BHK$1.23BHK$1.37BHK$2.50B
Total debtHK$807MHK$583MHK$506MHK$630MHK$657M

Quarterly statements and history in the cockpit →

Asymchem Laboratories (Tianjin) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%IBRXBANBCYTK99264528CORTKNSAGRF000963ALKEM600196AMRXORKA0126Z0BLTEALKSBIOCON6821.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Asymchem Laboratories (Tianjin) is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×40×60×BANB4528CORTKNSAGRF000963ALKEM600196AMRXALK-BBIOCON6821.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Asymchem Laboratories (Tianjin) is the large dot.

Asymchem Laboratories (Tianjin) competitors and peer comparison

Head to head with its named competitors (6821.HK vs 2359.HK vs 3759.HK vs LONN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Asymchem Laboratories (Tianjin) 6821.HK$7.10B+17%+24%17%24.4×n/a
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Pharmaron Beijing 3759.HK$9.65B+48%+24%14%20.8×n/a
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Siegfried SFZN.SW$3.51B-17%+4%16%16.8×n/a

How Asymchem Laboratories (Tianjin) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Asymchem Laboratories (Tianjin) against its 20 peers (data as of 18 Nov 2026)
Measure6821.HKPeer medianRank in peer set
1-month return-21.6%+2.2%4th lowest of 21
6-month return+16.6%-1.8%6th highest of 20
Distance from 52-week high-38.5%-16.5%7th lowest of 21
Revenue growth (TTM)+23.9%+8.9%6th highest of 18
Operating margin17.2%13.1%6th highest of 19
Forward P/E24.4×19.3×6th most expensive of 15
ROIC minus cost of capital+2.2 pp+0.2 pp8th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a

Questions

Who are Asymchem Laboratories (Tianjin)'s main competitors?
Named competitors: WuXi AppTec (2359.HK), Pharmaron Beijing (3759.HK), Lonza (LONN.SW), Siegfried Holding (SFZN.SW). The cockpit's measured peer set (industry) also includes ImmunityBio (IBRX), Bachem (BANB.SW), Cytokinetics (CYTK), Akeso (9926.HK), ONO Pharmaceutical (4528.T), Corcept Therapeutics (CORT).
Is Asymchem Laboratories (Tianjin) expensive compared with its peers?
On forward p/e it trades at 24.4× against a peer median of 19.3×, 6th most expensive of 15 in its peer set.
How has Asymchem Laboratories (Tianjin) stock performed?
Over six months to 18 Nov 2026 the shares returned +16.6% against -1.8% for the median peer; over one year +30.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.